Shares in Ipsos SA have recently benefitted from a regain of interest by market participants. The technical chart pattern suggests a continuation of the upward movement. Investors should benefit from the breakout of the € 25 level to target the € 28.5.
In a short-term perspective, the company has interesting fundamentals.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
Its low valuation, with P/E ratio at 10.9 and 9.36 for the ongoing fiscal year and 2021 respectively, makes the stock pretty attractive with regard to earnings multiples.
For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Technically, the stock approaches a strong medium-term resistance at EUR 24.3.
According to forecast, a sluggish sales growth is expected for the next fiscal years.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.